Shanghai Bio-heart Biological Technology Co., Ltd. (HKG:2185)
1.305
+0.020 (1.56%)
Oct 9, 2026, 3:58 PM HKT
HKG:2185 Revenue
Shanghai Bio-heart Biological Technology had revenue of 14.38M CNY in the half year ending June 30, 2026. This brings the company's revenue in the last twelve months to 38.45M, up 84.29% year-over-year. In the year 2025, Shanghai Bio-heart Biological Technology had annual revenue of 44.93M. That makes Shanghai Bio-heart Biological Technology the 39,532nd largest company in the world by revenue and 2,419th in Hong Kong.
Revenue (ttm)
38.45M CNY
Revenue Growth
+84.29%
P/S Ratio
7.16
Revenue / Employee
610.27K CNY
Employees
63
Market Cap
317.66M HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 44.93M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Uni-Bio Science Group | 549.77M |
| 3D Medicines | 412.66M |
| Cutia Therapeutics | 383.95M |
| Kintor Pharmaceutical | 90.90M |
| Wuhan YZY Biopharma | 67.26M |
| Brii Biosciences | 40.23M |
| Transcenta Holding | 32.70M |
| B&K Corporation | 602.64K |